Pharmaron Beijing Co., Ltd.

SEHK:3759 Voorraadrapport

Marktkapitalisatie: HK$51.2b

Pharmaron Beijing Toekomstige groei

Future criteriumcontroles 2/6

Pharmaron Beijing is forecast to grow earnings and revenue by 7.4% and 13.8% per annum respectively. EPS is expected to grow by 7.1% per annum. Return on equity is forecast to be 12.8% in 3 years.

Belangrijke informatie

7.4%

Groei van de winst

7.1%

Groei van de winst per aandeel

Life Sciences winstgroei50.3%
Inkomstengroei13.8%
Toekomstig rendement op eigen vermogen12.8%
Dekking van analisten

Good

Laatst bijgewerkt03 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

SEHK:3759 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202616,1122,2062,0343,12015
12/31/202514,1811,9711,7582,82317
12/31/202412,4471,819N/A2,51216
9/30/202411,7951,8843712,495N/A
6/30/202411,5021,9282582,573N/A
3/31/202411,4851,4833902,969N/A
12/31/202311,5381,601-1122,754N/A
9/30/202311,4241,553-2142,777N/A
6/30/202311,2721,575-5722,564N/A
3/31/202310,8871,474-8062,255N/A
1/1/202310,2661,375-8072,143N/A
9/30/20229,5451,582-7072,037N/A
6/30/20228,7931,682-3002,072N/A
3/31/20228,0571,664-2421,977N/A
12/31/20217,4441,661-352,058N/A
9/30/20216,8491,423-1521,905N/A
6/30/20216,2261,258-791,876N/A
3/31/20215,6641,3171251,822N/A
12/31/20205,1341,1723331,649N/A
9/30/20204,7171,0085321,565N/A
6/30/20204,3148654401,283N/A
3/31/20203,9535943701,124N/A
12/31/20193,757547184939N/A
9/30/20193,499437146837N/A
6/30/20193,274378247906N/A
3/31/20193,089346230861N/A
12/31/20182,908333150791N/A
9/30/20182,713300-721692N/A
12/31/20172,294231N/A552N/A
12/31/20161,634177N/A236N/A
12/31/20151,12874N/A217N/A
12/31/201479021N/A12N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 3759's forecast earnings growth (7.4% per year) is above the savings rate (2.3%).

Winst versus markt: 3759's earnings (7.4% per year) are forecast to grow slower than the Hong Kong market (11.5% per year).

Hoge groeiwinsten: 3759's earnings are forecast to grow, but not significantly.

Omzet versus markt: 3759's revenue (13.8% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Hoge groei-inkomsten: 3759's revenue (13.8% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 3759's Return on Equity is forecast to be low in 3 years time (12.8%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y